Edity is developing a novel delivery platform that uses immune cells to transfer therapeutic proteins to the target cells of patients. Our technology allows for precise modulation of intracellular pathways of disease using a range of proteins including gene editors, immune sensors, enzymes and intrabodies.
Company Details
- Employees
- 21
- Founded
- -
- Address
- Rehovot, Israel, Il
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- edity-tx.com
- HQ
- Rehovot, Israel
Edity Therapeutics Questions
Edity Therapeutics's website is edity-tx.com
Edity Therapeutics's LinkedIn profile is https://il.linkedin.com/company/edity-therapeutics
Edity Therapeutics has
21 employees.
View email and phone details for 21
employees at Edity Therapeutics.
Edity Therapeutics's industry is
Biotechnology Research
Edity Therapeutics's top competitors are
Cytoreason,
Mana.bio,
Evogene,
Aurigene Pharmaceutical Services Limited,
Renewalbio,
Applied Genomics,
Pepper Bio,
Noga Therapeutics,
Talus Bio,
Aurigene Oncology Limited.
Edity Therapeutics's categories are Biotechnology Research
Edity Therapeutics's founding year is 2020
